The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations

References

• Lethbridge-Çejku M, Rose D, Vickerie J. Summary health statistics for US adults: National Health Interview Survey, 2004. Washington, DC: US Department of Health and Human Services; 2006 July. Report No.: 228
   Google Scholar
• Dey AN, Bloom B. Summary health statistics for US children: National Health Interview Survey, 2003. Washington, DC: US Department of Health and Human Services; 2005 Mar
   Google Scholar
• 2004 Chartbook on Cardiovascular, Lung, and Blood Diseases, 2004 Available at: http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf. [Last accessed 2006 December 4]
   Google Scholar
• National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2002. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2002
   Google Scholar
• National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997. Report No.: NIH Publication No. 97–4051
   Google Scholar
• Workshop Report: Global Strategy for Asthma Management and Prevention. Scientific information and recommendations for asthma programs: In collaboration with the US National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO); 2002. Report No.: NIH Publication No. 02–3659
   Google Scholar
• National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: Update on selected topics 2002. Bethesda, MD: National Heart, Lung, and Blood Institute; 2003
   Google Scholar
• US Food and Drug Administration. Serevent Diskus, Advair Diskus, and Foradil Information (Long Acting Beta Agonists), 2006 Available at: http://www.fda.gov/cder/drug/infopage/LABA/default.htm. [Last accessed 2006 April 13]
   Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15–26
   PubMed Web of Science ®Google Scholar
• Serevent® Diskus® (salmeterol xinafoate inhalation powder). Full Prescribing Information, GlaxoSmithKline, Research Triangle Park, NC, 2006
   Google Scholar
• Foradil® Aerolizer® (formoterol fumarate inhalation powder). Full Prescribing Information, Novartis Pharma AG/Schering Corporation, Kenilworth, NJ, 2006
   Google Scholar
• Advair Diskus® Prescribing Information. Fluticasone propionate and salmeterol inhalation powder. Research Triangle Park, NC: GlaxoSmithKline 2006
   Google Scholar
• Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Mang Care Pharm 2007;13:44–52
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85–91
   Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535–44
   PubMed Web of Science ®Google Scholar
• US Department of Labor Bureau of Labor Statistics. Consumer Price Indexes., Available at: http://www.bls.gov/cpi/. [Last accessed 2007 August 1]
   Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368–73
   Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–44
   PubMed Web of Science ®Google Scholar
• van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999;54:207–12
   PubMed Web of Science ®Google Scholar
• Baraniuk J, Murray JJ, Nathan RA, et al. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. [see comment]. Chest 1999;116:625–32
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–7
   Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730–4
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337: 1405–11
   Google Scholar
• Ni-Chroinin M, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev 2005;CD005307
   Google Scholar
• Jackson CM, Lipworth B. Benefit-risk assessment of long-acting beta2-agonists in asthma. Drug Saf 2004;27: 243–70
   PubMed Web of Science ®Google Scholar
• McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924–30
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004;140: 802–13
   Google Scholar
• Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007;24:CD001385
   Google Scholar
• Shireman TI, Heaton PC, Gay WE, et al. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002;36:557–64
   PubMed Web of Science ®Google Scholar
• Stempel DA, O’Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109:433–9
   PubMed Web of Science ®Google Scholar
• Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999;160:211–15
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/ fluticasone propionate combination: a pharmaco economic review of its use in the management of asthma. Pharmacoeconomics 2003;21:951–89
   Google Scholar
• Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332–6
   PubMed Web of Science ®Google Scholar